Fuzheng Kangai Formula combined with first-line immunotherapy for non small cell lung cancer patients with middle or advanced stage: A retrospective study
Phase 2
Recruiting
- Conditions
- on small cell lung cancer
- Registration Number
- ITMCTR2024000133
- Lead Sponsor
- Guangdong provincial hospital of Chinese medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1) Patients who were pathologically and clinically diagnosed as an IIIA or IVB stage non-small cell lung cancer with at least one measurable lesion.
2) Patients who have been received at least 2 cycles of first line immunotherapy either alone or in combination with multiple therapies.
3) A outcome measure for evaluation.
4) Age was limited from 18 to 80 years old. Other baseline characteristics such as sex, PS score and PD-L1 expression were not limited.
Exclusion Criteria
1) Multiple primary malignancies coexist.
2) Case-related information is incomplete or unavailable
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival;
- Secondary Outcome Measures
Name Time Method Disease control rate;Objective response rate;Overall survival;Immune-related adverse reactions;